Approval · Notice of Compliance 7586 · 2005
ARIMIDEX: Notice of Compliance 7586
Issued November 1, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 7586
- Date
- November 1, 2005
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update - atac-5 year treatment completion analysis - post-approval commitment as per letter of undertaking dated june 30, 2004
- Therapeutic class
- Non-steroidal aromatase inhibitor
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ARIMIDEX | Not yet assigned | — |
Medicinal ingredients
- ANASTROZOLE 1 MG per TAB